SCHEMBL4743550

SCHEMBL4743550

Cc1cccc(-c2cc(Cl)c3nonc3c2)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AKR1C2 P52895 1/20 0.43
AKR1C1 Q04828 1/20 0.43
PBRM1 Q86U86 2/20 0.40
ENPP3 O14638 1/20 0.40
RAB9A P51151 5/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
NPC1 O15118 3/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
KMT2A Q03164 3/20 0.36
MAPK1 P28482 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
GRIN2B Q13224 1/20 0.36
MEN1 O00255 2/20 0.35
MAP4K4 O95819 1/20 0.35
DHODH Q02127 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5246540 0.83 MAP4K4 (0.41) ENPP3RAB9ASMN1; SMN2NPC1HPGD
SCHEMBL4744895 0.81 GRIN2B (0.39) RAB9ASMN1; SMN2NPC1HPGDKMT2A
SCHEMBL4745394 0.81 ADORA2A (0.44) RAB9ASMN1; SMN2NPC1HPGDKMT2A
SCHEMBL4786410 0.78 CASP3 (0.43) RAB9ASMN1; SMN2NPC1HPGDTSHR
SCHEMBL18932997 0.75 APP (0.44) RAB9ASMN1; SMN2NPC1HPGDTSHR
SCHEMBL14446368 0.75 MAPT (0.41) RAB9ASMN1; SMN2NPC1HPGDTSHR
SCHEMBL4785142 0.73 CHEK1 (0.47) ENPP3RAB9ASMN1; SMN2NPC1HPGD
SCHEMBL4746064 0.72 EPAS1 (0.37) RAB9ASMN1; SMN2NPC1HPGDTSHR
SCHEMBL4744881 0.70 KIF11 (0.41)
SCHEMBL4746821 0.70 ALDH1A1 (0.43) RAB9ASMN1; SMN2NPC1HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US claimed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO disclosed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO disclosed
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP AKR1C2 2298/4885AKR1C1 2453/4885PBRM1 2174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.